• Phosbind Biotin LC Western Blot Guide

  2026-09-01

  Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes when phospho-specific antibodies are unavailable or insufficient. It is intended for Western Blot workflows using streptavidin-HRP and chemiluminescence, but it should not be used in aqueous-only protocols or with solutions held for long-term storage.

• High-Content Screening of Schistosome Stem Cells

  2026-08-31

  The reference study developed a quantitative high-content platform that measures somatic neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. Screening a 280-compound stem cell-focused collection identified prioritized molecules that disrupted parasite development and stem cell proliferation, providing a more informative alternative to morphology- or motility-only assays.

• Pam3CSK4 TFA for TLR1/2 Activation Workflows

  2026-08-31

  Pam3CSK4 TFA provides a defined, tunable way to model TLR1/2-driven inflammation in primary cells, multiplex cytokine assays, and carefully controlled animal studies. Its strongest translational use is pairing ex vivo receptor stimulation with biomarkers such as IL-17A to distinguish pathway competence from clinical infection risk.

• Alda 1: Practical ALDH2 Assay Guidance

  2026-08-30

  Learn how Alda 1, SKU B5508, can support reproducible ALDH2-centered viability, proliferation, and cytotoxicity workflows. This scenario-driven guide covers variant compatibility, compound handling, data interpretation, and practical supplier-selection criteria for biomedical laboratories.

• CLCC1 and Membrane Fusion in Herpesvirus Egress

  2026-08-29

  The reference preprint identifies CLCC1 as a host factor required for the membrane-fusion step of herpesvirus nuclear egress, a process that releases capsids from the perinuclear space into the cytoplasm. Its combined genetic, imaging, virological, and comparative evidence links CLCC1 to both viral egress and nuclear pore complex insertion, while also suggesting that this membrane-remodeling function is evolutionarily ancient.

• CH 223191 for AhR Signaling Studies

  2026-08-29

  CH 223191 provides a practical receptor-level perturbation strategy for separating AhR-dependent transcription from broader inflammatory or toxic responses. Its nanomolar activity supports workflows spanning TCDD toxicity mechanism studies, CYP1A1 readouts, and microbiota–tryptophan–AhR research in intestinal repair models.

• Measuring Drug Response Beyond Viability

  2026-08-28

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent features of anticancer drug response. Its response-resolved framework helps researchers design assays that separate cytostatic effects from cell killing and interpret timing, potency, and mechanism more accurately.

• Benzyl-activated Streptavidin Magnetic Beads

  2026-08-28

  This product captures and magnetically separates biotinylated proteins, peptides, antibodies, sugars, oligonucleotides, and nucleic acids from complex samples. It is appropriate for enrichment, immunoprecipitation, interaction assays, and screening workflows, but should not be treated as a universal low-background reagent or as automatically compatible with live cells, enzymes, or every elution condition.

• IGF2BP3–FZD1/7 Drives Carboplatin Resistance in TNBC

  2026-08-27

  A 2025 Cancer Letters study identifies an IGF2BP3–FZD1/7 signaling axis that links m6A-dependent RNA stabilization to stem-like properties and Carboplatin resistance in triple-negative breast cancer. The work provides a mechanistic rationale for combining FZD1/7 inhibition with platinum treatment, while also defining experimental priorities for cancer research focused on cancer stem cells and DNA repair.

• Concerted Screening for Pancreatic Cancer Drugs

  2026-08-27

  Layeghi-Ghalehsoukhteh and colleagues developed a reporter-guided workflow that links primary pancreatic ductal adenocarcinoma cell screening with rapid in vivo validation. The study identified a gemcitabine, trichostatin A, and JQ1 combination that suppressed tumor initiation and progression, while illustrating how Rgs16::GFP can prioritize drug combinations for pancreatic cancer models.

• Lumiracoxib: Selective COX-2 Inhibitor Research

  2026-08-26

  Lumiracoxib is a selective COX-2 inhibitor used to investigate prostaglandin synthesis inhibition, inflammation, and vascular repair. In a mouse model of Bothrops asper venom-induced muscle injury, treatment produced time-dependent effects: early blockade worsened ischemia, whereas later responses included increased angiogenic and matrix-remodeling signals.

• Taltirelin Acetate: Applied Research Workflows

  2026-08-26

  Taltirelin acetate supports mechanism-led neuroprotection studies spanning dopaminergic neuron survival, oxidative stress, pathological protein cleavage, and behavioral outcomes. This practical guide connects literature-matched starting conditions with assay design, formulation handling, troubleshooting, and emerging applications in itch, sleep-disordered breathing, and oral dosage-form evaluation.

• Rocilinostat (ACY-1215) Workflow Guide

  2026-08-25

  Rocilinostat (ACY-1215) combines nanomolar HDAC6 potency with a workflow suited to multiple myeloma, combination-treatment, and exploratory cytoskeletal assays. This guide connects robust target-engagement measurements with the SMPD4–ceramide–primary cilium findings while clearly separating established evidence from cross-domain hypotheses.

• CSBTA Pharmacokinetics in MASH Mice

  2026-08-25

  The reference study integrates plasma pharmacokinetics, tissue distribution, cellular transport, metabolism, and regulatory signaling to explain why Corydalis saxicola Bunting total alkaloids behave differently in healthy and MASH-like mice. Its findings indicate that disease state and repeated dosing can increase exposure and hepatic accumulation of dehydrocavidine, palmatine, and berberine through coordinated changes in CYP450 enzymes and transporters.

• Cy3 TSA Fluorescence System Kit for Spatial Biology

  2026-08-24

  Discover how the Cy3 TSA Fluorescence System Kit converts HRP activity into localized signal amplification for IHC, ICC, and ISH. This article connects assay design with the TRIM66 olfactory receptor study to clarify when greater sensitivity improves biological interpretation—and when it can introduce ambiguity.

451 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page